Literature DB >> 18408364

Lack of an association between Alzheimer's disease and the cystatin C (CST3) gene G73A polymorphism in Mainland Chinese.

Binbin Wang1, Yan-chen Xie, Ze Yang, Dantao Peng, Jing Wang, Sirui Zhou, Shu Li, Xu Ma.   

Abstract

Alzheimer's disease (AD) is a complex multifactorial disorder involving a number of genetic and environmental factors. Cystatin C (CST3), which belongs to the type II cystatin gene family, is a potent inhibitor of lysosomal proteinases. Immunohistochemical studies have demonstrated the colocalization of the b-amyloid (A-beta) and cystatin C peptides within arteriolar walls in the AD brain. The G73A polymorphism of the CST3 genemay be associated with AD development. To investigate a possible association between the CST3 G73A polymorphism and late-onset AD (LOAD) in Mainland Chinese, we examined 281 LOAD patients and 376 healthy controls. All subjects were genotyped for CST3 and apolipoprotein E (APOE). There were no significant differences in the CST3 genotype or allele frequencies between the cases and the controls. Likewise, with the stratification of the APOE epsilon4 status, no statistical difference was observed between the cases and the controls. Our findings suggest that this polymorphism may not represent an additional genetic risk factor for LOAD in Mainland Chinese. (c) 2008 S. Karger AG, Basel

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18408364     DOI: 10.1159/000125670

Source DB:  PubMed          Journal:  Dement Geriatr Cogn Disord        ISSN: 1420-8008            Impact factor:   2.959


  8 in total

1.  Candidate gene analysis for Alzheimer's disease in adults with Down syndrome.

Authors:  Joseph H Lee; Annie J Lee; Lam-Ha Dang; Deborah Pang; Sergey Kisselev; Sharon J Krinsky-McHale; Warren B Zigman; José A Luchsinger; Wayne Silverman; Benjamin Tycko; Lorraine N Clark; Nicole Schupf
Journal:  Neurobiol Aging       Date:  2017-05-03       Impact factor: 4.673

Review 2.  APOE-4 genotype and neurophysiological vulnerability to Alzheimer's and cognitive aging.

Authors:  Susan Bookheimer; Alison Burggren
Journal:  Annu Rev Clin Psychol       Date:  2009       Impact factor: 18.561

Review 3.  Cystatin C in aging and in Alzheimer's disease.

Authors:  Paul M Mathews; Efrat Levy
Journal:  Ageing Res Rev       Date:  2016-06-19       Impact factor: 10.895

4.  Genetics of late-onset Alzheimer's disease: update from the alzgene database and analysis of shared pathways.

Authors:  Paolo Olgiati; Antonis M Politis; George N Papadimitriou; Diana De Ronchi; Alessandro Serretti
Journal:  Int J Alzheimers Dis       Date:  2011-12-10

5.  Cystatin C in Alzheimer's disease.

Authors:  Gurjinder Kaur; Efrat Levy
Journal:  Front Mol Neurosci       Date:  2012-07-06       Impact factor: 5.639

Review 6.  The Positive Side of the Alzheimer's Disease Amyloid Cross-Interactions: The Case of the Aβ 1-42 Peptide with Tau, TTR, CysC, and ApoA1.

Authors:  Lidia Ciccone; Chenghui Shi; Davide di Lorenzo; Anne-Cécile Van Baelen; Nicolo Tonali
Journal:  Molecules       Date:  2020-05-23       Impact factor: 4.411

7.  Associations of serum cystatin C with depressive symptoms and suicidal ideation in major depressive disorder.

Authors:  Ting Sun; Qian Chen; Yan Li
Journal:  BMC Psychiatry       Date:  2021-11-17       Impact factor: 3.630

8.  Evidence of Alternative Cystatin C Signal Sequence Cleavage Which Is Influenced by the A25T Polymorphism.

Authors:  Annie Nguyen; John D Hulleman
Journal:  PLoS One       Date:  2016-02-04       Impact factor: 3.240

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.